Patent assignee · US · COMPANY

PROMETHEUS BIOSCIENCES, INC.

🏢 View company profile →
15Patents
15Active
15Granted
51Portfolio score

Filing activity: May 20, 2016 → Feb 13, 2023

Most-cited patents

PatentTitleAreaCited byStatus
US10571467B2 Methods for prediction of anti-TNFα drug levels and autoantibody formation Physics 11 Active
US10689439B2 Optimized anti-TL1A antibodies Chemistry; Metallurgy 7 Active
US11053251B2 GPR35 modulators Chemistry; Metallurgy 3 Active
US11292848B2 Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof Chemistry; Metallurgy 3 Active
US11162943B2 Methods for assessing mucosal healing in Crohn's disease patients Emerging Cross-Sectional Technologies 2 Active
US11440954B2 Optimized anti-TL1A antibodies Chemistry; Metallurgy 2 Active
US11136386B2 Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) Chemistry; Metallurgy 2 Active
US10794906B2 Assays for detecting neutralizing autoantibodies to biologic therapy Physics 1 Active
US12215147B2 Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody Chemistry; Metallurgy 1 Active
US12391752B2 Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease Chemistry; Metallurgy 0 Active
US11866505B2 Anti-CD30L antibodies and uses thereof Chemistry; Metallurgy 0 Active
US10697961B2 Methods for predicting post-operative recurrence of Crohn's disease Physics 0 Active
US12305236B2 Methods and systems for selection and treatment of patients with inflammatory diseases Chemistry; Metallurgy 0 Active
US11999789B2 Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof Chemistry; Metallurgy 0 Active
US11773101B2 GPR35 modulators Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.